The FDA Pre-IND Meeting – A Best Practice for Mitigating Early Regulatory Risk

In this blog, Dr Eric Hardter, Associate Director of Regulatory Affairs, discusses the critical importance of proper planning and early engagement with FDA for Investigational New Drug (IND) applications.